Abstracts tagged "Juvenile idiopathic arthritis"

Abstract Number: 1634 • ACR Convergence 2020
Etiologies and Management of Hemophagocytic Lymphohistiocytosis: Is It Time for an Updated Protocol and Targeted Treatments?
Therese Posas-Mendoza¹, Cara McLeod¹, William Davis² and Robert Quinet², ¹Ochsner Medical Center, New Orleans, LA, ²Dept of Rheumatology, Ochsner Medical Center, New Orleans, LA
Background/Purpose: Hemophagocytic lymphohistiocytosis (HLH) is a rare life-threatening disease characterized by immune-overstimulation and a hyperinflammatory response resulting in cytokine storm and multi-organ failure.1 Secondary HLH…
Abstract Number: 0713 • ACR Convergence 2020
Longitudinal Effectiveness of Abatacept in JIA: Results from an Ongoing JIA Registry
Daniel J Lovell¹, Hermine Brunner², Nikolay Tzaribachev³, Esi Morgan², Gabriele Simonini⁴, Thomas Griffin⁵, Ekaterina Alexeeva⁶, John Bohnsack⁷, Andrew Zeft⁸, Gerd Horneff⁹, Richard Vehe¹⁰, Valda Stanevicha¹¹, Stacey Tarvin¹², Maria Trachana¹³, Adam Huber¹⁴, Ilonka Orban¹⁵, Jason Dare¹⁶, Ivan Foeldvari¹⁷, Pierre Quartier¹⁸, Alyssa Dominique¹⁹, Tzuyung Douglas Kou¹⁹, Robert Wong¹⁹, Alberto Martini²⁰ and Nicolino Ruperto²⁰, ¹PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ³Pediatric Rheumatology Research Institute, Bad Bramstedt, Germany, ⁴Anna Meyer Children's Hospital, Firenze, Italy, ⁵Levine Children's Hospital, Charlotte, NC, ⁶Scientific Center of Children’s Health of RAMS, Moscow, Russia, ⁷University of Utah and Primary Children's Hospital, Cincinnati, OH, ⁸Cleveland Clinic, Cleveland, OH, ⁹Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ¹⁰University of Minnesota, Minneapolis, MN, ¹¹Riga Stradins University, Riga, Latvia, ¹²Riley Children’s Health, Indianapolis, IN, ¹³Aristotle University of Thessaloniki, Thessaloníki, Greece, ¹⁴Dalhousie University, Halifax, NS, Canada, ¹⁵National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, ¹⁶University of Arkansas for Medical Sciences, Little Rock, AR, ¹⁷Hamburg Centre for Pediatric and Adolescent Rheumatology, Hamburg, Germany, ¹⁸Necker-Enfants Malades University Hospital, Assistance Publique-Hopitaux de Paris, Paris, France, ¹⁹Bristol-Myers Squibb Company, Princeton, NJ, ²⁰PRINTO, Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: Abatacept is a selective T-cell co-stimulation modulator approved for use in JIA. Efficacy and safety of abatacept in patients with JIA has been demonstrated…
Abstract Number: 0733 • ACR Convergence 2020
Practice Patterns for Tapering Medications in the Treatment of JIA-associated Uveitis
Ivan Foeldvari¹, Jens Klotsche², Sheila Angeles-Han³, Jordi Anton⁴, Gabriele Simonini⁵, Nadine Groesch² and Jean Baer⁶, ¹Head of the Hamburg Centre for Pediatric and Adolescence Rheumatology, Budapest, Hungary, ²German Rheumatism Research Center, Berlin, Germany, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Sant Joan de Déu Hospital, Madrid, Spain, ⁵Anna Meyer Children's Hospital, Firenze, Italy, ⁶Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany
Background/Purpose: Juvenile idiopathic arthritis associated uveitis (JIAU) is the most common extra-articular manifestation of JIA, and occurs in approximately 10% of affected children. Although there…
Abstract Number: 1682 • ACR Convergence 2020
Goal-Setting Improves Transition Readiness in Adolescents with Juvenile Idiopathic Arthritis and Systemic Lupus Erythematosus
Teresa Semalulu¹, Karen Beattie¹, Jeanine McColl¹, Arzoo Alam², Steffy Thomas², Julie Herrington³, Jan Willem Gorter², Tania Cellucci², Stephanie Garner¹, Liane Heale², Mark Matsos¹ and Michelle Batthish⁴, ¹McMaster University, Hamilton, ON, Canada, ²McMaster University, Hamilton, Canada, ³ACPAC - University of Toronto, Hamilton, ON, Canada, ⁴McMaster Children's Hospital, Hamilton, ON, Canada
Background/Purpose: The transition from pediatric to adult rheumatology care is associated with increased morbidity, mortality and loss to follow-up. This is largely due to a…
Abstract Number: 0714 • ACR Convergence 2020
Response to Abatacept in JIA Categories: Results from the PRCSG/PRINTO JIA Abatacept Phase IV Registry
Daniel J Lovell¹, Nikolay Tzaribachev², Esi Morgan³, Gabriele Simonini⁴, Thomas Griffin⁵, Ekaterina Alexeeva⁶, John Bohnsack⁷, Andrew Zeft⁸, Gerd Horneff⁹, Richard Vehe¹⁰, Valda Stanevicha¹¹, Stacey Tarvin¹², Maria Trachana¹³, Adam Huber¹⁴, Daniel Kietz¹⁵, Ilonka Orban¹⁶, Jason Dare¹⁷, Ivan Foeldvari¹⁸, Pierre Quartier¹⁹, Alyssa Dominique²⁰, Tzuyung Douglas Kou²⁰, Robert Wong²⁰, Alberto Martini²¹, Hermine Brunner³ and Nicolino Ruperto²², ¹PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Pediatric Rheumatology Research Institute, Bad Bramstedt, Germany, ³Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴Anna Meyer Children's Hospital, Firenze, Italy, ⁵Levine Children's Hospital, Charlotte, NC, ⁶Scientific Center of Children’s Health of RAMS, Moscow, Russia, ⁷University of Utah and Primary Children's Hospital, Cincinnati, OH, ⁸Cleveland Clinic, Cleveland, OH, ⁹Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ¹⁰University of Minnesota, Minneapolis, MN, ¹¹Riga Stradins University, Riga, Latvia, ¹²Riley Children’s Health, Indianapolis, IN, ¹³Aristotle University of Thessaloniki, Thessaloníki, Greece, ¹⁴Dalhousie University, Halifax, NS, Canada, ¹⁵Children’s Hospital of Pittsburgh, Pittsburgh, PA, ¹⁶National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, ¹⁷University of Arkansas for Medical Sciences, Little Rock, AR, ¹⁸Hamburg Centre for Pediatric and Adolescent Rheumatology, Hamburg, Germany, ¹⁹Necker-Enfants Malades University Hospital, Assistance Publique-Hopitaux de Paris, Paris, France, ²⁰Bristol-Myers Squibb Company, Princeton, NJ, ²¹PRINTO, Istituto Giannina Gaslini, Genova, Italy, ²²Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: Abatacept, a selective T-cell co-stimulation modulator, has been demonstrated to be well tolerated and effective in JIA in 2 Phase III studies.1,2 The ongoing…
Abstract Number: 0734 • ACR Convergence 2020
Differences and Similarities Between down Syndrome-associated Arthritis and Juvenile Idiopathic Arthritis in the New Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Jordan Jones¹, Chelsey Smith², Daniel J Lovell³ and Mara Becker⁴, ¹Children's Mercy Kansas City, Kansas City, MO, ²Children's Mercy Kansas City, Holden, MO, ³PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴Duke University School of Medicine, Durham, NC
Background/Purpose: Down syndrome-associated arthritis (DA) is under-recognized with delay in diagnosis (1). The majority of those with DA present with polyarticular, rheumatoid factor (RF) and…
Abstract Number: 1683 • ACR Convergence 2020
Ready or Not? Measuring Readiness for Transition to Adult Care in Adolescents with JIA & jSLE
Jeanine McColl¹, Teresa Semalulu¹, Arzoo Alam², Steffy Thomas², Julie Herrington³, Jan Willem Gorter², Tania Cellucci², Stephanie Garner², Liane Heale², Mark Matsos², Karen Beattie¹ and Michelle Batthish⁴, ¹McMaster University, Hamilton, ON, Canada, ²McMaster University, Hamilton, Canada, ³The Canadian Arthritis Society, Hamilton, Canada, ⁴McMaster Children's Hospital, Hamilton, ON, Canada
Background/Purpose: Transitioning from pediatric to adult care represents a particularly vulnerable period among patients with JIA and jSLE. The shift to adult care is often…
Abstract Number: 0715 • ACR Convergence 2020
JIA-ACR50 Response as a Predictor of Minimal Disease Activity in Patients Aged 2–17 Years with Polyarticular-Course JIA Treated with SC Abatacept
Nicolino Ruperto¹, Hermine I Brunner², Alberto Berman³, Francisco Ávila-Zapata⁴, Gerd Horneff⁵, Maria Alessio⁶, Mara Becker⁷, Alexandre Belot⁸, Ruben Burgos-Vargas⁹, Alina Boteanu¹⁰, Claudia Goldenstein-Schainberg¹¹, Iloite Scheibel¹², Maria Teresa Terreri¹³, Lawrence Zemel¹⁴, Robert Wong¹⁵, Margarita Askelson¹⁵, Marleen Nys¹⁶, Alberto Martini¹⁷ and Daniel J Lovell², ¹Istituto Giannina Gaslini, Genova, Italy, ²PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ³Universidad Nacional de Tucumán and Centro Médico Privado de Reumatología, Tucumán, Argentina, ⁴Star Medica Hospital, Merida, Yucatan, Mexico, ⁵Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ⁶Università di Napoli Federico II, Naples, Italy, ⁷Duke University School of Medicine, Durham, NC, ⁸Centre Hospitalier Universitaire de Lyon, Lyon, France, ⁹Department of Rheumatology, General Hospital of Mexico, Ciudad de Mexico, Mexico, ¹⁰Hospital Universitario Ramón y Cajal, Madrid, Spain, ¹¹University of São Paulo, São Paulo, Brazil, ¹²Hospital Criança Conceição, Porto Alegre, Brazil, ¹³Federal University of São Paulo, São Paulo, Brazil, ¹⁴Connecticut Children’s Medical Center, Hartford, CT, ¹⁵Bristol-Myers Squibb Company, Princeton, NJ, ¹⁶Bristol-Myers Squibb Company, Braine-L’Alleud, Belgium, ¹⁷PRINTO, Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: Effectiveness of SC abatacept in patients with polyarticular-course JIA (pJIA) was shown in a 2-year, open-label Phase III international study (NCT01844518). Here we assess…
Abstract Number: 1148 • ACR Convergence 2020
The SHARE Recommendations on Diagnosis and Treatment of Systemic JIA
Arjen Leek¹, Jordi Anton², Tadej Avcin³, Fabrizio De Benedetti⁴, Victor Boom¹, Claudia Bracaglia⁵, Paul Brogan⁶, Tamas Constantin⁷, Alessandro Consolaro⁸, Pavla Dolezalova⁹, Despina Eleftheriou¹⁰, Helen Foster¹¹, Claas Hinze¹², Isabelle Koné-Paut¹³, Kirsten Minden¹⁴, Francesca Minoia¹⁵, Pierre Quartier¹⁶, Angelo Ravelli⁸, Nicolino Ruperto¹⁷, Joost Swart¹⁸, Yosef Uziel¹⁹, Helmut Wittkowski²⁰, Carine Wouters²¹, Mojca Zajc Avramovitz²², Nico Wulffraat¹⁸ and Sebastiaan Vastert¹, ¹University Medical Center Utrecht, Utrecht, Netherlands, ²Sant Joan de Déu Hospital, Madrid, Spain, ³Ljubljana University Medical Centre, Ljubljana, Slovenia, ⁴Division of Rheumatology, Laboratory of Immuno-Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, ⁵Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, ⁶UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ⁷Semmelweiss University Hospital, Budapest, Hungary, ⁸Università degli Studi di Genova, Genoa, Italy, ⁹University Hospital Prague, Prague, Czech Republic, ¹⁰UCL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, Section Head Infection, Immunology, and Rheumatology, London, United Kingdom, ¹¹Newcastle University, Newcastle upon Tyne, United Kingdom, ¹²University Hospital M�nster, M�nster, Germany, ¹³Necker Hospital, Paris, France, ¹⁴Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ¹⁵Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, Milan, Italy, ¹⁶Necker-Enfants Malades University Hospital, Assistance Publique-Hopitaux de Paris, Paris, France, ¹⁷Istituto Giannina Gaslini, Genova, Italy, ¹⁸IRCCS Istituto Giannina Gaslini, PRINTO, Genoa, Italy, Genova, Italy, ¹⁹Meir Medical Center, Kfar Saba, Israel, ²⁰University Hospital Muenster, Muenster, Germany, ²¹University Hospital Leuven, Leuven, Belgium, ²²University Hospital Ljubljana, Ljubljana, Slovenia
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a rare, complex auto-inflammatory disease with significant morbidity including fever, rash, serositis and articular problems. With the availability…
Abstract Number: 1950 • ACR Convergence 2020
Elevated Serum Gasdermin D N-terminal Implicates Macrophage Pyroptosis in Adult-onset Still’s Disease and Systemic Juvenile Idiopathic Arthritis
Hideto Nagai¹, Yohei Kirino², Hiroto Nakano³, Yosuke Kunishita¹ and Michael Ombrello⁴, ¹Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan, ²Yokohama City University Graduate School of Medicine, Yokohama, Japan, ³NIAMS, NIH, Bethesda, ⁴Translational Genetics and Genomics Unit, NIAMS, NIH, Bethesda, MD
Background/Purpose: Elevation of serum IL-18 in adult-onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA) suggests involvement of one or more inflammasome in these…
Abstract Number: 0716 • ACR Convergence 2020
Variations in Adalimumab and Etanercept Dosing in Juvenile Idiopathic Arthritis and Their Effect on Treatment Outcome: A Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry Study
Ruud Verstegen¹, Peter Shrader², Stephen Balevic³, Timothy Beukelman⁴, Colleen Correll⁵, Anne Dennos⁶, Thomas Phillips² and Brian Feldman¹, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²Duke University, Durham, ³Duke University Medical Center, Durham, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵University of Minnesota, Minneapolis, MN, ⁶Duke University, Durham, NC
Background/Purpose: Different dosing strategies of adalimumab and etanercept have been used over the past decade in the treatment of juvenile idiopathic arthritis (JIA). With regards…
Abstract Number: 1149 • ACR Convergence 2020
Risk Score of Macrophage Activation Syndrome (MAS) in Patients with Systemic Juvenile Idiopathic Arthritis (sJIA)
Simone Carbogno¹, Denise Pires Marafon², Giulia Marucci², Emanuela Sacco², Manuela Pardeo², Alhanouf Alsaleem³, Sarka Fingerhutova⁴, Ferhat Demir⁵, Nastasia Cekada⁶, Mikhail Kostik⁷, Christoph Kessel⁸, Olga Vougiouka⁹, Alenka Gagro¹⁰, Jessica Tibaldi¹¹, Francesca Minoia¹², Ilaria Maccora¹³, Rayfel Schneider¹⁴, Pavla Dolezalova¹⁵, Betul Sozeri¹⁶, Marija Jelusic⁶, Antonella Insalaco², Fabrizio De Benedetti¹⁷ and Claudia Bracaglia², ¹Pediatric Area, University of Milan, Milan, Italy, ²Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, ³Division of Pediatric Rheumatology, Department of pediatrics, King Faisal specialist hospital and research center, Riyadh, Saudi Arabia, RiYADH, Saudi Arabia, ⁴Rheumatology Unit, Department of Paediatrics and Adolescent Medicine, Charles University in Prague, Dlouha 534, Kladno, 27201, Czech Republic, ⁵University of Health Sciences, Umraniye Tranining and Research Hospital Division of Pediatric Rheumatology, Istanbul, Turkey, Istanbul, Turkey, ⁶University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Croatia, Zagreb, Grad Zagreb, Croatia, ⁷Saint-Petersburg State Pediatric Medical University, Saint-Petersburg, Russia, Sto arrivando!, Russia, ⁸Department of Pediatric Rheumatology and Immunology, University Hospital Muenster, Muenster, Germany, Muenster, Germany, ⁹Second Department of Paediatrics, P. & A. Kyriakou Children’s Hospital, Athens, Greece, Athens, Greece, ¹⁰Children's Hospital Zagreb, Josip Juraj Strossmayer University of Osijek, Medical Faculty Osijek, Zagreb, Croatia, Zagreb, Grad Zagreb, Croatia, ¹¹UOC Clinica Pediatrica e Reumatologia, IRCCS Istituto Giannina Gaslini, Genoa, Italy, Genoa, Italy, ¹²Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, Milan, Italy, ¹³Paediatric Rheumatology Unit, Anna Meyer Children's University Hospital, School of Human Health Science, Florence, Italy, Florence, Italy, ¹⁴University of Toronto, The Hospital for Sick Children, Toronto, Canada, ¹⁵Paediatric Rheumatology and Autoinflammatory Diseases Unit, General University Hospital, Prague, Czech Republic, Prague, Czech Republic, ¹⁶University of Health Sciences, Umraniye Tranining and Research Hospital Division of Pediatric Rheumatology Istanbul, Turkey, Istanbul, Turkey, ¹⁷Division of Rheumatology, Laboratory of Immuno-Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy
Background/Purpose: Macrophage Activation Syndrome (MAS) is a severe, life-threatening, complication of Systemic Juvenile Idiopathic Arthritis (sJIA) with a significant mortality. A score that identify sJIA…
Abstract Number: 1983 • ACR Convergence 2020
Trajectories of Disease Activity in Patients with Newly Diagnosed Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
Natalie Shiff¹, Peter Shrader², Colleen Correll³, Anne Dennos⁴, Thomas Phillips² and Timothy Beukelman⁵, ¹Florida, Gainesville, FL, ²Duke University, Durham, ³University of Minnesota, Minneapolis, MN, ⁴Duke University, Durham, NC, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: To describe data-derived 2-year trajectories of disease activity in patients with recently diagnosed juvenile idiopathic arthritis (JIA) as measured by the clinical Juvenile Arthritis…
Abstract Number: 0717 • ACR Convergence 2020
Predictors of Clinical Remission in Children with Extended Oligoarticular Arthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis Treated with Etanercept in the CLIPPER Studies
Jelena Vojinovic¹, Vyacheslav Chasnyk¹, Joke Dehoorne¹, Violeta Panaviene¹, Jonathan Akikusa², Tadej Avcin¹, Jeffrey Chaitow¹, Bernard Lauwerys¹, Jordi Antón¹, Inmaculada Penades¹, Berit Flato¹, Alina Boteanu³, Hans-Iko Huppertz¹, Juan Jaller¹, Daniela Graham⁴, Cecilia Borlenghi⁵, Bonnie Vlahos⁶, Chuanbo Zang⁶ and Nicolino Ruperto², ¹Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ²PRINTO, Istituto Giannina Gaslini, Genova, Italy, ³Hospital Universitario Ramón y Cajal, Madrid, Spain, ⁴Pfizer, Groton, PA, ⁵Pfizer, New York, NY, ⁶Pfizer, Collegeville, PA
Background/Purpose: CLIPPER is an ongoing, 8-year, phase 3b, multicenter, open-label study of the safety and efficacy of etanercept in the treatment of juvenile idiopathic arthritis…
Abstract Number: 1150 • ACR Convergence 2020
Traditional Laboratory Parameters and New Biomarkers in Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis
Arianna De Matteis¹, Denise Pires Marafon¹, Ivan Caiello¹, Manuela Pardeo¹, Giulia Marucci¹, Emanuela Sacco¹, Giusi Prencipe¹, Fabrizio De Benedetti² and Claudia Bracaglia¹, ¹Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, ²Division of Rheumatology, Laboratory of Immuno-Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy
Background/Purpose: Macrophage Activation Syndrome (MAS) and secondary Hemophagocytic Lymphohistiocytosis (sHLH) are hyperinflammatory conditions caused by a cytokine storm, in which IFNγ plays a pivotal role.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].